Duro-Castano, Aroa England, Richard M. Razola, David Romero, Eduardo Oteo-Vives, Marta Morcillo, Miguel Angel Vicent, María J. Well-Defined Star-Shaped Polyglutamates with Improved Pharmacokinetic Profiles As Excellent Candidates for Biomedical Applications There is a need to develop new and innovative polymer carriers to be used as drug delivery systems and/or imaging agents owing to the fact that there is no universal polymeric system that can be used in the treatment of all diseases. Additionally, limitations with existing systems, such as a lack of biodegradability and biocompatibility, inevitably lead to side effects and poor patient compliance. New polymer therapeutics based on amino acids are excellent candidates for drug delivery, as they do not suffer from these limitations. This article reports on a simple yet powerful methodology for the synthesis of 3-arm star-shaped polyglutamic acid with well-defined structures, precise molecular weights (MW), and low polydispersity (<i>Đ</i> = <1.3). These were synthesized by ring-opening polymerization (ROP) of <i>N</i>-carboxyanhydrides (NCA) in a divergent method from novel multifunctional initiators. Herein, their exhaustive physicochemical characterization is presented. Furthermore, preliminary in vitro evaluation in selected cell models, and exhaustive in vivo biodistribution and pharmacokinetics, highlighted the advantages of these branched systems when compared with their linear counterparts in terms of cell uptake enhancement and prolonged plasma half-life. Pharmacokinetic Profiles;novel multifunctional initiators;side effects;acid;cell models;ROP;Biomedical ApplicationsThere;polymer carriers;limitation;MW;patient compliance;article reports;physicochemical characterization;Excellent Candidates;vivo biodistribution;New polymer therapeutics;drug delivery systems;drug delivery;cell uptake enhancement;NCA 2015-10-05
    https://acs.figshare.com/articles/journal_contribution/Well_Defined_Star_Shaped_Polyglutamates_with_Improved_Pharmacokinetic_Profiles_As_Excellent_Candidates_for_Biomedical_Applications/2125801
10.1021/acs.molpharmaceut.5b00358.s001